María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still benefited from ixazomib treatment.
Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis
Recent Articles
Quality of Generic Drugs Manufactured Overseas Comes into Question
The passage of the Hatch-Waxman Act in 1984, which created a regulatory track for generic drugs, marked the beginning of the generic-drug boom in...
Who Foots the Surprise Bill?
As U.S. Senators prepare for a July vote on proposed legislation that would protect patients from surprise medical bills, three key players in the...
Current Issue
May 2019, Volume 5, Issue 6
This issue features a look at home-based care for hematologic disorders, strides in pediatric leukemia in El Salvador, and more.
